Ann: Regeneus receives upfront payment of US$5.5m from AGC, page-14

$5201/AGC/Asahi Glass Co's acquisition of Copenhagen-based CMC Biologics may please Sydney-based $RGS/Regeneus.

This is because CMC Biologics will be a sister company to AGC/RGS's new Tokyo-based 50/50 venture to make and sell RGS's Progenza in Japan.

Progenza will be used for knee osteoarthritis.

One of CMC's key clients is Melbourne-based $CSL.

CMC supplies bulk drug intermediate for CSL Behring’s recently FDA-approved product, AFSTYLA [Antihemophilic Factor (Recombinant), Single Chain].

AFSTYLA is used for adults and children with hemophilia A. It reduces frequency of bleeding episodes.

“Working together with CSL Behring to achieve this important commercial milestone has been a major focus for our entire team in Copenhagen,” says Dr Patricio Massera, Site Head & General Manager of CMC Biologics’ Copenhagen facility.

“We are proud to have played an important role on the clinical development and manufacturing of the recombinant factor VIII single-chain of AFSTYLA.”